Head and Neck Cancer Clinical Trial Landscape

The head and neck cancer clinical trial landscape

Head and neck squamous cell carcinoma (HNSCC) encompasses cancers of the oral cavity, oropharynx, hypopharynx, and larynx, with nasopharyngeal carcinoma (NPC) as a biologically distinct entity. The HNSCC landscape is defined by two parallel clinical tracks: HPV-positive oropharyngeal cancer, increasingly common, younger patients, relatively favorable prognosis, and HPV-negative disease, which carries a worse prognosis and is associated with tobacco and alcohol exposure. These populations respond differently to treatment, and trials increasingly stratify by HPV status, PD-L1 CPS, and tumor subsite.

The checkpoint immunotherapy era transformed recurrent/metastatic HNSCC: pembrolizumab (Keytruda) is FDA-approved as first-line monotherapy for high CPS scores and in combination with chemotherapy for all-comers; nivolumab (Opdivo) is approved in platinum-refractory disease. As of 2026, the trial landscape is focused on three strategic fronts: (1) moving checkpoint benefit earlier into neoadjuvant and adjuvant settings, (2) combining checkpoint inhibitors with novel agents, EGFR/LGR5 bispecifics, EGFR×TGF-beta bifunctionals, LAG-3 inhibitors, therapeutic HPV vaccines, to address checkpoint-refractory patients, and (3) NPC-specific programs exploiting the EBV-driven biology that distinguishes NPC from conventional HNSCC.

The 2026 Phase 3 class is notably diverse. Petosemtamab (MCLA-158), Merus's EGFR×LGR5 bispecific with striking Phase 2 data, now has two registrational trials. BioNTech's BNT113 mRNA HPV16 vaccine represents the first therapeutic cancer mRNA vaccine in a HNSCC Phase 3. Ficerafusp alfa from Bicara targets EGFR and TGF-beta simultaneously. Together these represent a second wave of mechanistically distinct approaches beyond checkpoint monotherapy, the trial competitive intelligence question is no longer "checkpoint vs. nothing" but "which novel-checkpoint combination wins which patient subgroup."

• Bispecific antibodies, petosemtamab (EGFR×LGR5, Merus), amivantamab (EGFR×MET, Janssen), volrustomig (CTLA-4×PD-1, AstraZeneca)
• LAG-3/PD-1 checkpoint combinations, fianlimab + cemiplimab (Regeneron), anti-LAG-3 investigational combinations
• EGFR×TGF-beta bifunctionals, ficerafusp alfa/BCA101 (Bicara Therapeutics), combining EGFR blockade with TME immunosuppression relief
• Therapeutic HPV vaccines. BNT113 (BioNTech mRNA, HPV16 E6/E7), neoantigen peptide vaccines, VLP-based approaches for HPV+ oropharyngeal cancer
• Radioenhancers and novel radiosensitizers. NBTXR3 (hafnium oxide nanoparticles, J&J) activated by radiotherapy in LA-HNSCC
• Nasopharyngeal carcinoma programs. EBV-targeted T-cell therapies, tislelizumab + chemotherapy combinations, proton vs. photon IMRT comparative trials
• Neoadjuvant de-escalation, multiple Phase 3 trials for HPV+ low-risk oropharyngeal cancer testing RT + cetuximab vs. cisplatin to reduce toxicity

Active Phase 3 HNSCC and NPC trials (2026)

Key Phase 3 and pivotal head and neck cancer studies currently recruiting, active, or in startup, focused on programs with BD, CI, or investment relevance:

Petosemtamab (MCLA-158): EGFR×LGR5 bispecific, two Phase 3 programs

Petosemtamab is Merus's lead bispecific antibody targeting EGFR and LGR5, a Wnt pathway receptor expressed on cancer stem cells. The dual-targeting rationale addresses a known limitation of cetuximab (anti-EGFR monotherapy): EGFR blockade induces LGR5+ stem cell enrichment, which drives cetuximab resistance. By simultaneously blocking both targets, petosemtamab aims to eliminate both bulk tumor cells and the stem cell reservoir driving relapse.

Phase 2 data in platinum-refractory HNSCC showed a ~35% overall response rate, more than double the historical cetuximab benchmark of 13% in similar patients. The FDA granted Breakthrough Therapy designation. Merus subsequently launched two Phase 3 registrational trials covering the two most commercially significant HNSCC settings:

• LiGeR-HN1 (NCT06525220): Petosemtamab + pembrolizumab vs pembrolizumab in first-line R/M HNSCC. This is the pivotal trial for the 1L commercial indication, competing directly with pembrolizumab + chemotherapy standard of care.
• NCT06496178: Petosemtamab vs investigator's choice in second-line platinum-refractory HNSCC. Targeting the post-checkpoint progression setting where no effective options exist beyond cetuximab.

For CI teams, petosemtamab represents the most-watched drug in HNSCC right now, the first genuine mechanistic advance beyond pembrolizumab + chemotherapy to reach Phase 3. New trial registrations from Merus (combination studies, biomarker substudies) or competitor responses (other EGFR×X bispecifics entering Phase 1 in HNSCC) are high-value signals for the BD and investment community.

Fianlimab + cemiplimab: LAG-3 dual checkpoint combination enters Phase 3

Fianlimab is Regeneron's anti-LAG-3 antibody being developed with cemiplimab (Libtayo, anti-PD-1) as a dual checkpoint combination. The scientific basis mirrors Bristol Myers Squibb's relatlimab + nivolumab (Opdualag), FDA-approved in melanoma: PD-1 and LAG-3 are co-expressed on exhausted T cells in the tumor microenvironment, and dual blockade restores T cell function more effectively than either agent alone in tumors with high LAG-3 expression.

In first-line R/M HNSCC (NCT06769698), Regeneron is testing fianlimab + cemiplimab versus chemotherapy. This comparator arm is notable, by choosing chemotherapy rather than pembrolizumab, Regeneron avoids a direct statistical comparison with the approved pembrolizumab standard but also means the trial will need to beat platinum doublet chemotherapy to gain approval. If successful, it would establish LAG-3 combination as an alternative to pembrolizumab in the first-line setting, particularly for PD-L1-low patients where pembrolizumab monotherapy has limited benefit.

BNT113: BioNTech's therapeutic mRNA HPV vaccine in Phase 3

BNT113 is a lipid nanoparticle-formulated mRNA cancer vaccine encoding HPV16 E6 and E7 oncoproteins, the viral proteins that drive transformation and immortalization in HPV-positive oropharyngeal cancer. BNT113 is distinct from Gardasil/Cervarix (prophylactic HPV vaccines that prevent infection), it is a therapeutic vaccine designed to generate tumor-clearing cytotoxic T cell responses in patients with established HPV16-driven tumors.

The HNSCC Phase 3 trial (NCT04534205) evaluates BNT113 + pembrolizumab versus pembrolizumab alone in PD-L1-positive HPV16+ HNSCC patients, the hypothesis being that BNT113-induced tumor-specific T cells synergize with checkpoint blockade to produce deeper, more durable responses than checkpoint therapy alone. HPV16+ oropharyngeal cancer represents approximately 25–35% of all HNSCC in Western populations, and the well-defined tumor antigen (E6/E7) makes this a uniquely tractable target for therapeutic vaccination.

BNT113 is one of the first therapeutic cancer mRNA vaccines to reach a randomized Phase 3 registrational trial. Its success or failure will have broad implications for the therapeutic cancer vaccine field beyond HNSCC.

Ficerafusp alfa (BCA101): bifunctional EGFR/TGF-beta targeting

Ficerafusp alfa is a bifunctional fusion protein from Bicara Therapeutics: an anti-EGFR antibody backbone fused to a TGF-beta receptor II extracellular domain, creating a molecule that simultaneously blocks EGFR signaling on tumor cells and sequesters TGF-beta in the tumor microenvironment. HNSCC tumors characteristically secrete high levels of TGF-beta, which suppresses T cell infiltration and function, a potential mechanism of resistance to checkpoint inhibitors. By neutralizing both EGFR and TGF-beta, ficerafusp alfa aims to combine direct tumor growth inhibition with immunosuppression relief.

The FORTIFI-HN01 Phase 3 trial (NCT06788990) tests ficerafusp alfa + pembrolizumab versus pembrolizumab alone in first-line PD-L1-positive R/M HNSCC. This is an enriched population (PD-L1 CPS ≥1), consistent with the pembrolizumab CPS-stratified approval. Phase 2 data showed ORR of approximately 50% in PD-L1-high patients, significantly above pembrolizumab historical rates. If Phase 3 confirms these results, ficerafusp alfa would become the first approved bifunctional EGFR/TGF-beta therapeutic.

Nasopharyngeal carcinoma (NPC): a distinct competitive landscape

Nasopharyngeal carcinoma warrants monitoring as a separate entity from HNSCC. NPC is driven by Epstein-Barr virus (EBV) infection and has a distinct geographic pattern, incidence is 20–30× higher in Southeast Asia and southern China compared to Western populations. The biology is fundamentally different from tobacco/alcohol-driven HNSCC: EBV-encoded antigens (LMP1, LMP2, EBNA) provide tumor-specific targets, and NPC tumors are consistently PD-L1 high.

The NPC trial landscape in 2026 is dominated by Chinese academic and industry sponsors, with Sun Yat-sen University running multiple Phase 3 programs. Key strategic signals to watch:

• Immunotherapy optimization: Multiple Phase 3 trials testing different PD-1 inhibitor combinations (tislelizumab, toripalimab, sintilimab) with and around chemoradiotherapy, establishing which combination and timing maximizes benefit in locally advanced NPC
• Proton vs. photon IMRT: NCT07340515 is a Phase 3 comparative effectiveness trial, a major infrastructure investment that signals confidence in proton centers as an NPC treatment standard in China
• ADC programs: MRG003 (EGFR-targeted ADC from MiRXES) entering Phase 2 in R/M NPC alongside international ADC programs, following the ADC playbook from breast and urothelial cancer into NPC
• Anlotinib combination: Multi-kinase inhibitor + immunotherapy + chemoradiotherapy Phase 3 in high-risk NPC (Sun Yat-sen), adding VEGFR/FGFR/PDGFR inhibition to the immunotherapy backbone

Western-sponsored companies with NPC programs (Zymeworks, Jazz Pharmaceuticals) tend to register trials on both ClinicalTrials.gov and Chinese registries. A new ClinicalTrials.gov registration from a Western sponsor targeting EBV antigens or testing an ADC in NPC is an early-stage BD signal worth tracking.

Antibody-drug conjugates in HNSCC: a maturing competitive front

Following ADC success in breast cancer and urothelial carcinoma, the class is advancing in HNSCC. Tisotumab vedotin (TV), targeting tissue factor (TF), demonstrated Phase 2 single-agent activity in HNSCC and is in combination trials with pembrolizumab and chemotherapy. Patritumab deruxtecan (HER3-DXd) is being explored given high HER3 expression in HNSCC. Several novel EGFR-targeted ADCs with differentiated linker-payload designs are entering Phase 1, exploiting the established EGFR overexpression in HNSCC, each new Phase 1 HNSCC registration from an EGFR-ADC program is a potential partnering signal 12–18 months before pivotal trials.

Who uses head and neck cancer trial monitoring

• Oncology BD and licensing teams: tracking ADC, bispecific, and HPV-vaccine programs entering Phase 1/2 as licensing or co-development targets before pivotal data; monitoring Merus, Bicara, Regeneron as potential acquisition candidates if Phase 3 data is positive
• Oncology investors and fund analysts: monitoring petosemtamab Phase 3 enrollment pace and interim signal readouts; tracking BNT113 as the key therapeutic cancer vaccine readout in 2026–2027
• Head and neck oncology CROs: identifying new sponsor relationships and site networks across complex multi-modality (chemoradiation + immunotherapy + novel agent) trial designs
• Medical affairs at checkpoint inhibitor sponsors: watching fianlimab, petosemtamab, and ficerafusp alfa Phase 3 results as competitive threats to pembrolizumab's 1L HNSCC franchise
• NPC-focused teams: monitoring Asian-sponsor trials on ClinicalTrials.gov and tracking EBV-targeted and ADC programs entering the NPC space

What we monitor for head and neck cancer

Our pipeline pulls from ClinicalTrials.gov every day. For an HNSCC/NPC watch profile, your digest can cover:

• Conditions: head and neck squamous cell carcinoma, HNSCC, oropharyngeal cancer, laryngeal cancer, oral cavity cancer, nasopharyngeal carcinoma, NPC, hypopharyngeal cancer
• Key drug targets and agents: petosemtamab, fianlimab, cemiplimab, pembrolizumab, nivolumab, amivantamab, BNT113, NBTXR3, ficerafusp alfa, volrustomig, cetuximab, tisotumab vedotin
• Phase filters: Phase 1 (novel agents entering HNSCC), Phase 3 (registration-enabling programs)
• Sponsor type: large pharma (MSD/Merck, Regeneron, AstraZeneca, BioNTech), emerging biotech (Merus, Bicara Therapeutics), academic cooperative groups (EORTC, NRG Oncology, ECOG-ACRIN)
• Settings: neoadjuvant, adjuvant, 1L R/M (checkpoint combination era), 2L+ (post-checkpoint), locoregional recurrence

Frequently asked questions